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Elimination of filariasis requires a macrofilaricide treatment that can
be deliveredwithin a 7-day period. Here we have identified a synergy
between the anthelmintic albendazole (ABZ) and drugs depleting the
filarial endosymbiont Wolbachia, a proven macrofilaricide target,
which reduces treatment from several weeks to 7 days in preclinical
models. ABZ had negligible effects onWolbachia but synergized with
minocycline or rifampicin (RIF) to deplete symbionts, block embryo-
genesis, and stop microfilariae production. Greater than 99%Wolba-
chia depletion following 7-day combination of RIF+ABZ also led to
accelerated macrofilaricidal activity. Thus, we provide preclinical
proof-of-concept of treatment shortening using antibiotic+ABZ com-
binations to deliver anti-Wolbachia sterilizing and macrofilaricidal
effects. Our data are of immediate public health importance
as RIF+ABZ are registered drugs and thus immediately implement-
able to deliver a 1-wk macrofilaricide. They also suggest that
novel, more potent anti-Wolbachia drugs under development
may be capable of delivering further treatment shortening, to
days rather than weeks, if combined with benzimidazoles.
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Lymphatic filariasis (LF) and onchocerciasis present a signifi-cant global health burden, affecting an estimated 120 million
and 38 million people, respectively (1–3). The causative agents
of LF are the filarial nematodes Wuchereria bancrofti, Brugia
malayi, and Brugia timori. Symptomatically, LF presents as lym-
phedema and hydrocele and, in more advanced cases, as el-
ephantiasis (1, 2). Onchocerciasis is caused by the filaria
Onchocerca volvulus and is associated with skin disease. In ad-
vanced untreated cases onchocerciasis can result in blindness
caused by the immune response to migration and death of
microfilariae (mf) in the eye (1, 3).
The standard antifilarial anthelmintics albendazole (ABZ),
diethylcarbamazine (DEC), and ivermectin (IVM) are currently
the mainstay of mass drug administration (MDA) elimination
programs for filariasis. Standard antifilarial drug MDA regimens
(delivered annually) do not deliver substantial curative efficacy
but rather temporarily reduce the levels of mf in the blood or
skin. While DEC and IVM are direct microfilaricides, ABZ in-
hibits mf production. ABZ/DEC combination treatment is used
in MDA programs to eliminate LF, except in Africa, where an
ABZ/IVM combination is used due to contraindications of DEC
in onchocerciasis (1). Recently, a clinical trial administering a
single triple-dose combination of IVM/DEC/ABZ has shown
superior microfilaremia suppression in bancroftian filariasis for
up to a year (4). These promising results have the potential to
accelerate LF elimination goals, in situations where the absence
of Loa loa and/or O. volvulus coendemicity precludes the risk of
severe adverse events. For onchocerciasis elimination, MDA
programs use IVM administered as a monotherapy in all en-
demic areas. Although targeting mf has proved effective in
elimination of LF and onchocerciasis in certain country settings
(5–7) the strategy has failed either to deliver expected outcomes
or has not yet been deployed sustainably in many regions of sub-
Saharan Africa (8–10). In particular, the use of IVM is prob-
lematic in geographical regions where L. loa is coendemic, as this
can result in severe adverse reactions (SAEs) caused by drug-
induced death and associated inflammation of blood-borne
L. loa mf in the brain (11). These SAEs can result in encepha-
lopathy, coma, and death (12). Epidemiological simulations also
predict MDA will not interrupt transmission in certain scenarios
(13, 14). Alternative treatment strategies are therefore required
to achieve the WHO global elimination targets of LF and on-
chocerciasis. Ideally these should be short-course treatments
delivering safe macrofilaricidal (curative) efficacy (15).
The bacterial symbiont Wolbachia is essential for the devel-
opment, growth, and survival of many filarial parasites, including
the causative agents of LF and onchocerciasis (15). Effective
targeting of Wolbachia with tetracycline or rifamycin antibiotics
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induces growth retardation, embryostasis, and blockade of mf
release in preclinical models of filariasis (16–18). Through a
series of pivotal clinical trials, doxycycline (DOX) has demon-
strated embryostatic, transmission-blocking, and curative effica-
cies against LF and onchocerciasis (19–24). Importantly, anti-
Wolbachia treatments are safe to administer in loiasis coendemic
areas because L. loa lacks Wolbachia symbiosis and DOX does
not affect Loa microfilaraemias (22, 25). Further, the slow
waning of mf in the circulation or the skin and gradual adult
parasite death of the anti-Wolbachia mode of action avoids the
inflammatory adverse reactions associated with rapid-acting di-
rect filaricidal agents, in part by avoiding the liberation of Wol-
bachia as classical inflammatory inducers (21, 26–28). However,
long treatment durations with DOX are required for significant
antifilarial effects to be induced, related to a sustained >90% de-
pletion level of the endosymbiont from filarial tissues after drug
removal (29–31). Interestingly, sterilization of female filariae
without significant macrofilaricidal activity (assessed up to 2 y after
treatment) has been demonstrated clinically with a reduced
treatment duration of DOX (3 wk vs. 4 wk), where Wolbachia was
depleted >80% but <90% from nematode tissues (21). This sug-
gests that a lower threshold depletion level of Wolbachia may still
mediate sustained transmission-blocking activity in the treatment
of LF and onchocerciasis (and disease-blocking activity in the case
of onchocerciasis). Through pharmacokinetic–pharmacodynamic
(PK-PD) modeling we have recently identified that the related
second-generation tetracycline minocycline (MIN) may reduce
overall treatment time in humans compared with DOX (18).
Rifampicin (RIF) has been shown to exhibit superior anti-
Wolbachia potency in vitro and in vivo in models of LF and
onchocerciasis compared with the tetracycline class (32–34).
However, these observations have not translated into superior
efficacy in clinical trials vs. DOX when administered at the
“standard” 10 mg/kg dose for 2 or 4 wk to patients with oncho-
cerciasis (35, 36). We have been able to explain this discrepancy
based on RIF PKs and drug exposures recorded in preclinical
models compared with humans. We have identified that a min-
imum dosage of RIF bioequivalent to 30–40 mg/kg in humans is
required to deplete Wolbachia beyond the 90% threshold pre-
dictive of clinical cure (21, 29, 34). Reassuringly, fourfold dose
elevations of RIF have recently been identified as safe when
delivered for periods of 1 mo (37) in patients with TB, suggesting
that RIF at a high dose could be deployed as a short-course
macrofilaricidal drug for human use.
The global challenge is to develop a macrofilaricidal treatment
that can be delivered in 7 d or less. In an effort to achieve these
treatment times in this study we evaluated whether ABZ could
enhance the anti-Wolbachia activities of the registered antibiotics
MIN or RIF. Our results confirm substantial synergy between
ABZ and both the tetracycline and rifamycin class of anti-
Wolbachia drugs. Moreover, this synergy leads to long-term
sterilizing effects and reduced treatment courses to 7 d. Un-
expectedly, combining the most potent anti-Wolbachia regimen,
high dose (HD)-RIF, with ABZ in a 7-d treatment also medi-
ated an accelerated macrofilaricidal effect as well as signifi-
cantly improvingWolbachia depletion beyond the 90% theshold in
surviving adult female filariae, predictive of long-term asymbiotic
macrofilaricidal activity.
Results
Benzimidazole Anthelmintics Do Not Directly Deplete Intracellular
Wolbachia. The multiple-dose PKs of clinically bioequivalent
ABZ were parameterized in CB.17 SCID mice (see PK-PD
Modeling). ABZ is essentially a prodrug which is almost com-
pletely converted to the pharmacologically active metabolite
albendazole sulphoxide (ABZ-SOX) in vivo; this is further
converted to the pharmacologically inactive secondary metabo-
lite albendazole sulphone (ABZ-SON). In our bioanalyses, the
parental ABZ molecule was found to be below the limit of
quantification in all sampled time points. Monte Carlo simula-
tions were used to calculate murine dosage regimens that gave
bioequivalent exposures of the active metabolite ABZ-SOX
in mice to the standard clinical dose of 400 mg ABZ. The dis-
tribution of human exposures to ABZ were based on PK
parameters from the literature (38–44). From simulations we
determined a 5 mg/kg twice daily (bid) murine dosage regimen
for ABZ closely emulated overall daily exposure of ABZ-SOX
following a standard 400-mg clinical dose (mean exposure
400 mg ABZ in humans = 7.1 ± 5.0 μg·h/mL ABZ-SOX, and
mean exposure 5 mg/kg bid in SCID mice = 7.7 ± 5.2 μg·h/mL
ABZ-SOX; Fig. 1).
Following the determination of the bioequivalent dose of ABZ
in SCID mice we assessed whether pharmacologically relevant
ABZ exposures had any direct effect on filarial Wolbachia in
vivo. Groups of SCID mice with 6-wk-old adult B. malayi in-
fections were dosed with vehicle control, bioequivalent 400 mg
ABZ (5 mg/kg bid) or ABZ two- to fourfold in excess of bio-
equivalency (10 or 20 mg/kg bid) for +7 d. MIN (25 mg/kg bid)
was used as an anti-Wolbachia positive control (Fig. 2A). One
day after the last dose, total Wolbachia loads were enumerated
from female B. malayi (Fig. 2B). Treatment with MIN for +7 d
mediated a significant 77% median reduction in Wolbachia
compared with vehicle controls. However, +7 d ABZ did not
significantly reduce Wolbachia loads in B. malayi at the bio-
equivalent 400-mg human dose or up to fourfold higher expo-
sures (Fig. 2B). Adult parasite loads were not affected by any
ABZ treatment (SI Appendix, Table S1). We further assessed
whether a range of benzimidazole (BZ) drugs, including the
ABZ metabolites ABZ-SOX and ABZ-SON, could reduce
Wolbachia titres in an in vitro insect cell assay at 5 μM contin-
uous exposure over +7 d (Fig. 2C). No BZ compound was ef-
fective at depleting insect Wolbachia, whereas the DOX positive
control reduced Wolbachia loads by between 1–2 log.
ABZ Synergizes with Short-Course Antibiotic Treatments to Enhance
Depletion of Wolbachia and Sustainably Block Filarial Embryogenesis.
MIN is a superior anti-Wolbachia tetracycline in vivo compared
with DOX yet is predicted to require a dosing period of >2 wk to
Fig. 1. Human equivalent murine dosing regimens were calculated by
Monte Carlo simulations.
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deliver >90% depletion levels and blockade of embryogenesis in
female filariae (18). Suboptimal dosages of tetracyclines lead to
gradual Wolbachia recrudescence following drug removal (45).
We therefore examined long-term effects of combining ABZ
during the final 3 d of a suboptimal 15-d MIN regimen in a
chronic gerbil model of brugian filariasis. Gerbils were implanted
with 10 mature female and male B. malayi ip and after 1 wk were
treated orally with MIN for 15 d [100 mg/kg once daily (qd)],
ABZ (13 mg/kg qd) or MIN for 15 d in combination with ABZ
for the final 3 d of dosing (Fig. 3A). Gerbils were left for a
protracted washout period of 8 mo following the start of treat-
ment before adult filariae and mf were recovered and enumer-
ated. qPCR analysis confirmed that neither ABZ nor MIN
monotherapy mediated a significant Wolbachia depletion within
female B. malayi, compared with vehicle control worms (ABZ:
17% median depletion vs. vehicle, MIN: 40% median depletion).
In comparison, MIN+ABZ combination significantly synergized
in the depletion of Wolbachia from adult female B. malayi by
approximately twofold (MIN+ABZ: 84% Wolbachia depletion).
The synergy in Wolbachia depletion was specific to female
B. malayi because no drug treatment significantly impacted
Wolbachia loads within male B. malayi after +8 mo washout (Fig.
3C). The parasitological effects of targeting Wolbachia with
ABZ, MIN, or MIN+ABZ combination were assessed. All ve-
hicle and drug-treated animals contained viable adult filariae
+8 mo after implantation and no significant differences were
apparent in adult yields (SI Appendix, Table S2). Vehicle control-
treated animals contained 1.9 × 106 ± 0.5 × 106 (mean ± SEM)
viable peritoneal mf (Fig. 3D). Gerbils treated with MIN or ABZ
monotherapies contained similar levels of mf, whereas the
MIN+ABZ combination treatment had significantly reduced
peritoneal mf reduced on average by 77.9% (0.4 × 106 ± 0.2 ×
106 viable peritoneal mf).
Because of the synergism observed at the level of Wolbachia
depletion and reduced mf burdens following MIN+ABZ com-
bination, we next evaluated whether synergy was also observable
when combining ABZ with the more potent anti-wolbachial
agent RIF. RIF regimens, previously defined as bioequivalent
to either “standard” (∼10 mg/kg) or “high” (∼30 mg/kg) clinical
regimens (34) were tested. Groups of SCID mice with 7-wk-old
adult B. malayi infections were dosed with vehicle control, bio-
equivalent 400 mg ABZ (5 mg/kg bid) bio-equivalent, standard-
dose (SD)-RIF (5 mg/kg qd), HD-RIF (35 mg/kg qd) or com-
binations of SD-RIF or HD-RIF+ABZ, all for +7 d (Fig. 4A).
An additional group of SCID mice were dosed with 100 mg
bioequivalent DOX (25 mg/kg bid DOX) for +42 d, as a positive
control (46). Six weeks after dose commencement, total Wolba-
chia loads were enumerated from female and male B. malayi
(Fig. 4 B and C). As previously defined, +7 d bioequivalent ABZ
did not significantly impact Wolbachia loads in female B. malayi
and, further, did not significantly reduce Wolbachia within male
B. malayi. SD-RIF also did not significantly reduce Wolbachia
load in female B. malayi. Combinations of SD-RIF+ABZ en-
hanced the Wolbachia depletion in female B. malayi approxi-
mately twofold compared with SD-RIF alone, which was
significant compared with vehicle control levels (48.5% de-
pletion, SD-RIF monotherapy vs. 83.3% median depletion SD-
RIF+ABZ). In contrast, Wolbachia depletion in male B. malayi
was not enhanced following treatment with the SD-RIF+ABZ
combination (83% vs. 79%). As demonstrated in previous
studies (34), HD-RIF monotherapy induced significant, >90%
threshold levels of Wolbachia depletion in female B. malayi
Fig. 2. Schematic of drug treatment protocol (A). Wolbachia loads in B. malayi females immediately following 7-d exposure with MIN or ABZ at indicated
doses (B). Box and whiskers are median, minimum/maximumWolbachia surface protein (wsp) gene copy number, derived from a pool of 10 individual worms,
sourced from groups of four SCID mice. Significant differences are assessed by Kruskal–Wallis one-way ANOVA (female wormWolbachia depletions Kruskal–
Wallis statistic: 21.79, P = 0.0002) with Dunn’s multiple tests: *P < 0.05, **P < 0.01. (C) Change inWolbachia load compared with vehicle control following 7-d
exposure to listed compounds (all 5 μM) within an A. albopictus cell line stably infected with wAlbB (C6/36 wAlbB). Bars are mean log-fold change (+SEM)
from triplicate wells from two individual experiments.
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(97.3%) and >99% threshold depletion in male B. malayi
(99.2%). However, combinations of HD-RIF+ABZ elevated the
median Wolbachia depletion level further from >90% to >99%
threshold efficacy compared with HD-RIF monotherapy (99.3%
vs. 97%). This anti-Wolbachia synergy was again specific to fe-
male filariae, because the degree of Wolbachia depletion in male
B. malayi following HD-RIF+ABZ compared with HD-RIF
monotherapy was unchanged (99.3% vs. 99.2%). The level of
Wolbachia depletion in female or male B. malayi following a
42-d, 100-mg human dose equivalent of DOX (25 Mk bid) is given
as a comparison where a 99.7% median depletion was evident in
female B. malayi; only the HD-RIF+ABZ combination achieved a
similar, >99% threshold level of depletion matching long-course
DOX, in female B. malayi, when dosed for +7 d.
The parasitological consequences of RIF+ABZ anti-Wolba-
chia synergy within female B. malayi were scrutinized. Analysis
of embryogenesis in female B. malayi following ABZ, RIF, or
RIF+ABZ combination treatments was undertaken (Fig. 5).
Early-stage embryos were not significantly reduced in female
B. malayi uteri following standard-dose ABZ 7-d monotherapy
vs. vehicle controls (Fig. 5A). Further, late-stage embryonic
stages (“pretzel” stage, coiled embryos and stretched in-
trauterine mf) were variable and not significantly different
following ABZ monotherapy vs. vehicle controls (Fig. 5B).
Short-course RIF treatments, irrespective of dose and combi-
nation with ABZ, significantly reduced early-stage embryos vs.
either vehicle controls or ABZ monotherapy treatment (Fig.
5A). However, only combinations of SD-RIF+ABZ or HD-
RIF+ABZ mediated significant reductions in late-stage intrauterine
developmental stages vs. vehicle controls (Fig. 5B). In the case of
HD-RIF+ABZ, a complete absence of late-stage embryonic stages
was apparent within female B. malayi. When measuring fecundity,
accumulations of mature, motile mf were consistently present in
vehicle controls (eight of eight mice, 0.11 × 106 median viable
peritoneal mf, range 0.06–0.14 × 106). ABZ (six of six mice) or
standard-dose RIF (four of four mice) groups also contained vi-
able mf and peritoneal microfilarial loads were not significantly
reduced vs. vehicle group (Fig. 5C). In comparison, mature mf
were completely absent in the peritonea of mice treated with HD-
RIF monotherapy (zero of four mice) or combinations of either
SD-RIF+ABZ (zero of eight mice) or HD-RIF+ABZ (zero of
eight mice).
Total B. malayi adult worm burdens were significantly reduced
following treatment with HD-RIF+ABZ vs. ABZ monotherapy
(47.5% median reduction) (Fig. 6). No other treatment signifi-
cantly affected total worm burdens recovered 6 wk postdosing.
When examining sex-specific effects, female worm recoveries
were significantly reduced following HD-RIF+ABZ vs. ABZ
monotherapy (60.7% median reduction) while male worm bur-
dens were not significantly different in any treatment group.
Lack of Evidence for a Drug–Drug Interaction When Coadministering
ABZ+RIF. RIF is a known autoinducer of the cytochrome P450
system, although we have shown previously that there is no
autoinduction after a 7-d dose of RIF in our mouse model (34).
To scrutinize whether coadministration of RIF+ABZ altered the
systemic exposures of either RIF or the ABZ active metabolite
ABZ-SOX, the PK of RIF and ABZ-SOX after combination
treatment for +5 d at clinically bioequivalent dosages was char-
acterized. For RIF, a standard 600-mg dose in humans yields
exposures of 55.1 μg·h/mL (34), whereas in mice a qd 5 mg/kg
dose administered gives an exposure 46.7 ± 16.0 μg·h/mL A
Fig. 3. Schematic of drug treatment protocol (A). Wolbachia loads in B. malayi females (B), Wolbachia loads in B. malayi males (C), and peritoneal B. malayi
microfilarial loads per gerbil (D), +8 mo postimplantation of adult filariae and commencement of 15-d vehicle, ABZ, MIN, or MIN+ABZ combination treat-
ments (ABZ administered for final 3 d) at indicated doses. Box and whiskers are median, minimum/maximum Wolbachia surface protein (wsp) gene copy
number, adjusted for heterogeneity in filarial age as a ratio to the B. malayi GST (gst) gene, derived from a pool of 10 individual worms, sourced from groups
of six gerbils. Significant differences in Wolbachia load are assessed by Kruskal–Wallis one-way ANOVA, female worm Wolbachia depletions Kruskal–Wallis
statistic: 21.2, P < 0.0001; male worm Wolbachia depletions Kruskal–Wallis statistic: not significant with Dunn’s multiple comparisons tests. *P < 0.05, ***P <
0.001. Significant differences in peritoneal mf number are assessed by one-way ANOVA with Holm–Sidak’s multiple comparisons tests *P < 0.05.
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one-compartment model with absorptive gut compartment was
found to describe the data best for both monotherapy and
combination therapy data. Fig. 7 shows the simulated profiles for
clinically bioequivalent ABZ and RIF when given separately and
in combination with experimentally sampled drug concentrations
superimposed. By comparing the PK parameters of clinically
bioequivalent dosages of RIF and ABZ-SOX we determined
that the chronic exposures for both ABZ-SOX and RIF did not
significantly vary when given in combination in comparison with
those determined for the monotherapies (Table 1). This result
was confirmed using sparsely sampled concentrations from
monotherapy and combination therapy efficacy studies, as these
were found to be routinely within the simulated bounds for the
monotherapy PK profiles and there was no systematic deviation
for combination therapy drug concentrations in comparison
with the monotherapy concentrations (SI Appendix, Fig. S4).
Levels of the terminal ABZ-SON metabolite were similarly
unaffected by combination chronic dosing with RIF (SI Ap-
pendix, Fig. S4 C and D).
Discussion
Our data reveal a pharmacological drug synergy between regis-
tered classes of antibiotics when combined with the standard
antifilarial drug ABZ in targeting the filarial symbiont Wolba-
chia. The impact of this synergy is to reduce treatment time to as
little as 1 wk to substantially deplete symbionts with concomitant
long-term embryostatic activities, total inhibition of mf pro-
duction, and accelerated killing of female worms.
Wolbachia populate two major tissues within female filariae,
the hypodermal chord syncytium and the germline (47). The
latter population is thought to become stably infected via
transfer of hypodermal Wolbachia into germline stem cells dur-
ing development of female gonads within fourth-stage larvae, at
8–11 d postinfection (48). Wolbachia then rapidly divide during
oogenesis (35–50 bacteria per egg) (49). Following fertilization
of female worms,Wolbachia further divide and spread in zygotes,
by asymmetric mitotic segregation, into the embryonic stem cell
precursor of the lateral chord and subsequently expand within
the primordial microfilarial hypodermal chord (100–200 Wol-
bachia per mf; refs. 48–50). At this part of the life cycle, Wol-
bachia symbiosis provides an essential source of nucleotides and
micronutrient pathways (FAD, heme, and riboflavin) to support
the high demand on biosynthesis during rapid oogenic/embryonic
cell division (47). Thus, effective depletion of the germline
Wolbachia filarial population may lead to a highly localized de-
ficiency in growth and survival factors necessary for embryo-
genesis. Indeed, antibiotic treatment of B. malayi and effective
Fig. 4. Schematic of drug treatment protocol (A). Wolbachia loads in B. malayi females (B) or males (C), +13 wk postinfection and +6 wk after com-
mencement of 7-d vehicle, ABZ, RIF, ABZ+RIF combination treatments, or DOX treatment for +42 d at indicated doses. Box and whiskers are median,
minimum, and maximum Wolbachia surface protein gene copy number, derived from a pool of 10 individual worms, sourced from groups of three to four
mice. Significant differences are assessed by Kruskal–Wallis one-way ANOVA (female worm Wolbachia depletions Kruskal–Wallis statistic: 49.7, P < 0.0001;
male worm Wolbachia depletions Kruskal–Wallis statistic: 37.1, P < 0.0001) with Dunn’s multiple tests, indicated as *P < 0.05, **P < 0.01, ***P < 0.001, or
****P < 0.0001 (only tests compared with vehicle are shown).
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depletion of Wolbachia induces apoptosis of embryonic and
uterine tissues, which is consistent with permanent sterility (51).
Because anti-Wolbachia synergy was only reproducibly observed
in female rather than in male adult filarial tissues following ABZ+
antibiotic drug treatments, we hypothesize that the synergistic
activity of ABZ+antibiotic combination targets the germline
Wolbachia population, preventing their division, spread, and ap-
propriate asymmetric localization in oocytes and embryos. While
the precise mechanism by which ABZ augments anti-Wolbachia
activity remains to be identified, as a nematode β-tubulin poly-
merization inhibitor ABZ potentially interferes with intracellular
locomotion of dividingWolbachia along microtubules, thus enhancing
Fig. 5. Quantification of early intrauterine embryonic stages (A) and late intrauterine embryonic stages (B) in B. malayi females and accumulations of
mature, motile i.p. B. malayi mf (C), +13 wk postinfection and +6 wk after commencement of 7-d vehicle, ABZ, RIF, or combination treatments at indicated
doses. Box and whiskers are median levels, minimum/maximum of indicated uterine stage/s or mature, motile i.p. mf. Embryogram data are derived from a
pool of five individual females, sourced from groups of three to four mice; i.p. mf counts are derived from four mice per group (RIF monotherapies), six mice
per group (ABZ monotherapy), or eight mice per group (vehicle and RIF+ABZ combinations). Significant differences are assessed by one-way ANOVA with
Holm–Sidak’s multiple comparison tests (early-stage embyos/female worm F = 6.537, P = 0.0006) or Kruskal–Wallis one-way ANOVA with Dunn’s multiple
comparisons tests (late-stage embryos/female worm Kruskal–Wallis statistic: 19.8, P = 0.0014, peritoneal mf/mouse Kruskal–Wallis statistic: 35.5, P < 0.0001).
Significance of multiple comparisons tests are indicated: *P < 0.05, **P < 0.01, or ****P < 0.0001.
Fig. 6. Quantification of total (A), female (B), and male (C) B. malayi worm burdens +13 wk postinfection and +6 wk after commencement of 7-d vehicle,
ABZ, RIF, or combination treatments at indicated doses. Box and whiskers are median percent recoveries (100 BmL3 infections) and minimum/maximum of
mature, motile adult stages from four mice per group (RIF monotherapies) seven mice per group (ABZ monotherapy) or eight mice per group (vehicle and
RIF+ABZ combinations). Significant differences are assessed by Kruskal–Wallis one-way ANOVA with Dunn’s multiple comparisons tests (total worm burden
Kruskal–Wallis statistic: 12.6, P = 0.0274; female worm Kruskal–Wallis statistic: 11.8, P = 0.0379). Significance of multiple comparisons tests are indicated
as *P < 0.05.
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a bacteriostatic antibiotic mode of action. Albeit using con-
centrations far in excess of the in vivo pharmacological range,
Wolbachia division along microtubules within a Drosophila cell
line or B. malayi can be disrupted following in vitro ABZ expo-
sures, causing a phenomenon of Wolbachia elongation (52). The
effect of ABZ on Wolbachia elongation was limited to the germ-
line population in female B. malayi. Further, because BZs target
rapidly dividing cells and have established embryotoxic effects
(53, 54), temporary disruption of nematode oogenesis and em-
bryogenesis by ABZ may prevent residual Wolbachia titres from
Fig. 7. Simulated PK profiles (day 1) for (A) 5-d 5 mg/kg bid ABZ regimen. (B) ABZ in ABZ+RIF combination 5-d regimen. (C) The 5-d 5 mg/kg qd RIF regimen
(day 1). (D) RIF in ABZ+RIF combination regimen. For the simulated PK profiles the solid line represents the median profile and the red dashed lines represent
the 5th and 95th percentile PK profiles and blue circles experimentally sampled concentrations.
Table 1. Pharmacokinetic parameters for chronically dosed clinically bioequivalent RIF, ABZ, and RIF+ABZ
Parameter
ABZ monotherapy
(n = 8)
ABZ combination
therapy (n = 5)
RIF monotherapy
(n = 3)
RIF combination
therapy (n = 5)
CL/F, mL/(h·kg) 868 ± 323 724 ± 256 167 ± 4 156 ± 80
V/F, mL/kg 2,187 ± 846 2,572 ± 694 1,871 ± 314 3,857 ± 1,167
ka 4.2 7.8 1.0 ± 0.5 2.4 ± 0.7
AUC24 h—day 5, μg·h/mL 7.7 ± 5.2 8.9 ± 4.2 46.7 ± 16.0 30.0 ± 11.5
AUC24 h—day 5, 24-hour exposure for day 5; CL/F, apparent clearance; ka, rate constant for absorption; V/F, apparent volume of
distribution.
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recrudescing within the germline niche following removal of
otherwise suboptimal, short-course antibiotic exposures.
We adopted PK modeling to align our preclinical registered
drug exposures with documented human exposures. Thus, we are
encouraged that the synergy observed in our SCID mouse pre-
clinical model of filariasis is likely to bridge into the clinical
setting, using combinations of safe dosages for which there is
already considerable human experience. Importantly, this may
allow for treatment shortening of 7 d or less with an anti-Wolbachia
targeted approach, to exert permanent sterility of LF and Oncho-
cerca infections. Because both ABZ and RIF are safe to administer
in loiasis patients, this potentially could translate to a one-off short-
term administration strategy delivering sterilizing and curative ac-
tivities against LF and onchocerciasis in patients coinfected with
L. loa infection, in hard-to-reach areas of forested central and west
Africa. These observations come at an important time as the related
BZ drug flubendazole, which is more potent than ABZ in pre-
clinical models and demonstrably macrofilaricidal in onchocerciasis
patients when administered as an intramuscular injection, is under
development as an oral reformulation (55) capable of delivering a
macrofilaricide effect. However, rigorous regulatory preclinical
safety testing has confirmed that this drug is too toxic for human
use. This observation may blight the developability of other directly
acting BZs such as the veterinary BZ oxfendazole, which is un-
dergoing repurposing in humans as a neglected tropical disease
indication with the potential for onchocerciasis testing in the future
(56). Therefore, if synergy between anti-Wolbachia drugs and the
BZ class is consistently demonstrable in preclinical models,
there is the potential to explore a strategy of combining anti-
biotics with lowered doses of novel human BZ indications with
more robust safety profiles, to exert permanent sterility and
cure of filarial infections with single administration period of
7 d or less.
Recently, ABZ monotherapy given semiannually has been
demonstrated to deliver significant long-term (2 y) reductions in
circulating mf in African LF patients (57). Trials in onchocerciasis
with variable length and dose of ABZ (3–10 d) have provided
evidence that, as a monotherapy, ABZ can mediate a degree of
filarial embryotoxicity and impact skin microfilarial levels re-
sponsible for disease and transmission (58, 59). Further, in a recent
pilot trial combining ABZ for the final 3 d of a 3-wk DOX treat-
ment in onchocerciasis patients demonstrated increased efficacy at
the level of embryogenesis blockade compared with DOX mono-
therapy, demonstrating that ABZ+antibiotic synergy translates to
the clinic (60). Our preclinical data provide strong proof-of-
concept that by combining more potent anti-Wolbachia regimens
with ABZ a total block of embryogenesis can be mediated within a
7-d timeframe. These observations provide a strong rational for
immediate clinical evaluation of these synergistic combinations in
LF and onchocerciasis patients. Future work should also examine
the effects of combining the “next-generation” anti-Wolbachia
candidates being developed from drug discovery programs (61, 62),
which have improved potency and reduced treatment timeframes
compared with DOX, with ABZ (or other repurposed/reformu-
lated BZ anthelmintics) with the goal of reducing treatment
timeframes to less than 7 d.
The potential translational medicine impact of our documented
antifilarial drug combination synergy is a treatment shortening to
days, rather than weeks, of a safe, well-tolerated macrofilaricide
regimen, compatible with all target populations, with the potential
to deliver “end-game” elimination of LF and onchocerciasis.
Materials and Methods
Parasites. The B. malayi (Bm) filarial nematode parasite life cycle [TRS strain
(63)] was maintained in mosquitoes and susceptible M. unguiculatus gerbils
at Liverpool School of Tropical Medicine (LSTM) or TRS laboratories. Infective
Bm larvae (BmL3) were bred via procedures as previously described (64).
Briefly, mf collected from infected gerbils by catheterization (65) were fed to
female adult Aedes aegypti; mf were mixed with human blood and fed to
mosquitoes using an artificial membrane feeder (Hemotek). BmL3-stage
larvae were propagated by rearing the blood-fed mosquitoes for 14 d.
BmL3 larvae were then harvested from infected mosquitoes by crushing and
purification (64).
Animals. Male BALB/c CB17 SCID mice were obtained from Harlan Labora-
tories. Outbred M. unguiculatus gerbils were bred at LSTM or TRS labora-
tories. All animals were housed under specific pathogen-free conditions at
approved animal housing facilities. Ethical approval was obtained for all
animal experiments at LSTM from the relevant animal welfare committees
at the University of Liverpool and LSTM. Experiments were conducted
according to Home Office or US national requirements.
Parasite Infections and Implantations. One hundred freshly isolated B. malayi
L3 larvae were injected intraperitoneally into CB.17 SCID mice. Inoculation
efficiencies were confirmed by needle washout. For B. malayi implantations,
gerbils were anesthetized and 10 mature female and male B. malayi were
surgically implanted into the peritoneum, as previously described (64).
Preparation and Administration of Drug Compounds. All drugs were given at
stated concentrations and durations, as a solution via oral gavage, 6–7 wk
after infection or 1 wk after implantation. Rodents were administered with
100 μL of ABZ, DOX, MIN, or RIF. For combination therapy, 200 μL containing
a 1:1 mixture of two compounds was administered. DOX and MIN were
dissolved in water. RIF was dissolved in 55% polyethylene glycol 300, 25%
propylene glycol, and 20% water and ABZ was dissolved in standard sus-
pension vehicle composed of 0.5% carboxymethyl cellulose, 0.5% benzyl
alcohol, 0.4% Tween 80, and 0.9% NaCl. All reagents were purchased from
Sigma unless otherwise stated.
Parasitological Readouts. Mice were necropsied at either 7 or 13 wk post-
infection as indicated. RPMImediumwas used in peritoneal washes to recover
adults and mf. After isolation, adult worms were stored overnight in fresh
medium at 4 °C before being washed in cold PBS. Adult stages were then
enumerated and their sex determined. For qPCR analysis ofWolbachia loads,
10–15 female adults were analyzed per treatment group, derived from each
screen. Between two and four female worms were selected, randomly, from
individual mice, to avoid bias due to intragroup dosing variation. mf were
pelleted from peritoneal washings by centrifugation (300 g, 5 min, 4 °C, low
brake) and resuspended in 1–2 mL of medium and the total mf quantity
contained within peritoneal lavage was enumerated by microscopy.
Quantification of Wolbachia Bacteria Numbers Using qPCR Assay. DNA ex-
traction from individual female worms was performed using a DNeasy Blood
and Tissue Kit (Qiagen) in accordance with the manufacturer’s instructions.
Quantification of Bm Wolbachia wsp copy numbers was performed using
qPCR as previously described (50).
Determination of in Vitro Potencies. The anti-Wolbachia potency of a range of
BZs was determined in vitro, utilizing an insect cell screening assay as de-
scribed previously (61). Briefly, the mosquito (Aedes albopictus) derived cell
line (C6/36), stably infected with Wolbachia pipientis (wAlbB) (C6/36 wAlbB)
were incubated with a panel of BZ compounds, DOX (all 5 μM, dissolved in
DMSO), or 1% DMSO control for 7 d with 2,000 cells per well on a 384-well
plate (CellCarrier-384 Ultra; PerkinElmer) in Leibovitz media (Life Technol-
ogies) supplemented with 20% FBS (Fisher Scientific), 2% tryptose phos-
phate broth (Sigma-Aldrich), and 1% nonessential amino acids (Sigma-
Aldrich). The end-point readout utilized DNA staining of both the host cell
nuclei and intracellular Wolbachia (SYTO11) combined with a high-content
imaging system (Operetta; PerkinElmer) and analyzed using the associated
Harmony software through a cytoplasm texture analysis.
Pharmacokinetic Studies in CB.17 SCID Mice. Rich PK studies were conducted to
determine the PKs of ABZ 5 mg/kg bid and RIF 5 mg/kg qd regimens ad-
ministered orally as monotherapies for 5 d. PK of a single dose of 10 mg/kg
in uninfected BALB/c CB.17 SCID mice was also determined. ABZ, the primary
metabolite ABZ-SOX, and the secondary metabolite ABZ-SON were all
quantified in these rich PK studies. These studies were conducted to assess
PK at steady state and also linearity as bioavailability-limited dose-dependent
PKs have been reported in humans (41, 42).
The PKs of RIF and ABZ when given in combination were also characterized
via rich PK studies in uninfected CB.17 SCID mice (weight 24–28 g); RIF and ABZ
were administered in combination at 5 mg/kg qd and 5 mg/kg bid for 5 d. All
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dosage regimens were administered via oral gavage in the appropriate vehicles,
matching administrations used in PD studies. Blood samples were collected
using microsampling from the tail vein for all studies. For the monotherapy
studies serial blood samples were collected up to 24 h after a single dose and
after the last dose for the chronic dosing regimen. For the combination therapy
study serial blood samples were collected up to 6 h after dosing.
In all cases 20-μL blood samples were collected using a pipette with a
preheparinized tip. Samples were immediately lysed with 40 μL of ice-cold
double-distilled (dd) H2O and then frozen at −80 °C until time of analysis.
Sparse samples were obtained from the PD studies in the B. malayi CB.17
SCID murine infection model to ensure that drug exposures after combina-
tion therapies were in line with those observed in the rich PK studies.
Bioanalysis. RIF and ABZ whole-blood drug concentrations were quantified
using liquid chromatography–MS on a UPLC (ultrahigh-pressure liquid
chromatography) system linked to a triple-quadruple TSQ Quantum Ac-
cess mass spectrometer (Thermo Scientific) with a heated-electrospray
ionization source.
For RIF chromatic separation was achieved using previously validated
protocols (34). For ABZ and its metabolites ABZ-SOX and ABZ-SON chro-
matographic separation was achieved using an isocratic method consisting
of methanol:water (50:50, vol/vol). Separation was achieved using reverse-
phase chromatography carried out on a Hypersil C8 Gold column (50 ×
2.1 mm, 1.9-μm particle size; Thermo Scientific). All methods used the ap-
propriate internal standards and were validated using Food and Drug Ad-
ministration guidelines which are internationally recognized (66).
To a 20-μL aliquot of blood lysate 180 μL of ddH2O was added plus 800 μL
of dichloromethane/hexane/methyl-tert-butyl ether (1/1/1) containing
1,000 ng/mL of internal standard sulfisoxazole. Samples were then vortexed
for 10 s and centrifuged at 13,000 × g for 10 min. A 750-μL aliquot was then
taken from the supernatant and evaporated to dryness at 30 °C, under a
gentle stream of nitrogen. The residue was then reconstituted in 120 μL of
methanol:water (50:50, vol/vol) and transferred to 300-μL clean, dry, glass
vials. A 10-μL aliquot was then subjected to UPLC-MS/MS analysis.
For RIF, protocols from previous studies for calibration and quantification
were followed (34). For ABZ, ABZ-SOX, and ABZ-SON, a whole-blood cali-
bration curve (range 50–2,000 ng/mL) was run alongside blood samples;
quality-control samples at low 50 ng/mL, medium 1,000 ng/mL, and high
1,500 ng/mL concentrations were used for ABZ, ABZ-SOX and ABZ-SON, re-
spectively. All standard curves were described using an equal weighted lin-
ear regression equation using the data acquisition software LC Quan
(version 2.5.6; Thermo Scientific). The correlation coefficients (r2) for ABZ,
ABZ-SOX, and ABZ-SON calibration curves all exceeded 0.97.
The lower limit of quantification (LLOQ) is described as the lowest possible
concentration on the calibration curve and is validated using an LLOQ sample
which has an accuracy determined by its relative error ± 20% and a precision
determined by its relative SD of less than 20%.
PK-PD Modeling. All pharmacokinetic modeling and simulations was per-
formed using Pmetrics (67) within R version 3.1.0 (68). PK models were built
for both monotherapies and combination therapies using sample concen-
trations from rich PK studies. ABZ is almost completely converted to the
active metabolite ABZ-SOX in-vivo, then it is further converted to the
pharmacological inactive secondary metabolite ABZ-SON. Given the dose
dependency reported in previous PK studies in clinical and murine studies,
dose-specific parameters were fitted. Pharmacokinetic models fitting drug
concentrations for the pharmacologically active metabolite of interest ABZ-
SOX were constructed. The final model incorporated a one-compartment
model with an absorptive gut compartment for oral dosing as detailed by
the differential equations 1a and 1b (SI Appendix, Fig. S1):
dX1
dt
=−kaX1 [1a]
dX2
dt
= kaX1 −

CL
V

X2, [1b]
where X1 and X2 are the amounts of ABZ and ABZ-SOX in the absorptive and
central compartments, representing gut and systemic circulation, re-
spectively. The pharmacokinetic parameters ka, CL, and V denote the ab-
sorption rate constant, apparent clearance, and volume of distribution,
respectively. In this instance ka is a lumped parameter including rate of
conversion from ABZ to ABZ-SOX as the parent drug was found to be below
the limit of quantification in all sampled time points for monotherapy and
combination therapy. A two-compartment model with absorptive gut
compartment simultaneously fitting ABZ-SOX and ABZ-SON was also con-
structed (SI Appendix, Figs. S2 and S3 and Table S3). The final model showed
a good fit of both metabolites but was not used further as the primary
metabolite model was a slightly better fit for the pharmacologically active
metabolite and PK parameters were simpler to interpret.
Model fitting was performed using protocols defined previously (69, 70).
Briefly, the goodness-of-fit of the observed/predicted values (population
and individual predictions) were assessed by linear regression (intercept
close to 0, slope close to 1), the coefficient of determination of the linear
regression (R2 close to 1.0), and log-likelihood values. A statistically signifi-
cant improvement in the log-likelihood value (P, 0.05) was required for a
more complex model to be supported.
Statistical Tests. The continuous variables wsp copy number, total B. malayi
worm count, female B. malayi worm count, and male B. malayi worm count
were not normally distributed following log transformations, determined by
D’Agostino and Pearson omnibus tests. Therefore, statistical significance was
assessed by Kruskal–Wallis tests followed by Dunn’s multiple comparisons
tests post hoc comparing three or more groups.
The continuous variable total peritoneal mf count was normally distrib-
uted, determined by D’Agostino and Pearson omnibus tests. Statistical sig-
nificance was assessed two-tailed, one-way ANOVA with Holm–Sidak’s
multiple comparisons tests post hoc comparing three or more groups. Sig-
nificance level was set to alpha = 0.05.
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